Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immunome (IMNM) EBITDA (2023 - 2025)

Immunome's EBITDA history spans 3 years, with the latest figure at -$72.9 million for Q4 2025.

  • For Q4 2025, EBITDA rose 12.18% year-over-year to -$72.9 million; the TTM value through Dec 2025 reached -$224.1 million, up 26.71%, while the annual FY2025 figure was -$224.1 million, 26.71% up from the prior year.
  • EBITDA reached -$72.9 million in Q4 2025 per IMNM's latest filing, down from -$60.1 million in the prior quarter.
  • In the past five years, EBITDA ranged from a high of -$4.5 million in Q1 2023 to a low of -$132.3 million in Q1 2024.
  • Average EBITDA over 3 years is -$53.3 million, with a median of -$48.5 million recorded in 2024.
  • Peak YoY movement for EBITDA: crashed 2859.05% in 2024, then skyrocketed 66.26% in 2025.
  • A 3-year view of EBITDA shows it stood at -$94.7 million in 2023, then grew by 12.34% to -$83.0 million in 2024, then grew by 12.18% to -$72.9 million in 2025.
  • Per Business Quant, the three most recent readings for IMNM's EBITDA are -$72.9 million (Q4 2025), -$60.1 million (Q3 2025), and -$46.5 million (Q2 2025).